首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens.
【24h】

Effect of intranasal azelastine and beclomethasone dipropionate on nasal symptoms, nasal cytology, and bronchial responsiveness to methacholine in allergic rhinitis in response to grass pollens.

机译:鼻内氮卓斯汀和倍氯米松双丙酸酯对过敏性鼻炎中对草花粉反应的鼻症状,鼻细胞学和支气管对乙酰甲胆碱反应的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: We compared the effect of nasal azelastine (0.56 mg/day), nasal beclomethasone dipropionate (BDP, 200 micrograms/day) and matched placebo on seasonal symptoms, nasal cytology, and the increase in bronchial responsiveness occurring during pollen season in a group of subjects with history of allergic rhinitis to grass pollens only. METHODS: The study was completed by nine subjects in the azelastine group, 13 subjects in the BDP group, and 13 subjects in the placebo group. Treatments were randomly administered for 6 weeks. Each subject recorded daily nasal, eye and chest symptoms and additional treatment requirement for the entire pollen season. Each subject performed nasal lavage 4 weeks into the pollen season. Bronchial responsiveness to methacholine was measured before and 4 weeks into the pollen season. Response was expressed as provocative dose causing a 20% fall in forced expiratory volume in 1 second in micromoles. RESULTS: Azelastine-treated subjects had significantly fewer nasal symptoms during week 4 (p < 0.05), and BDP-treated subjects had fewer nasal symptoms during week 4 (p < 0.05) and week 5 (p < 0.05) compared with subjects given placebo. Both treatments significantly reduced the need for additional medications. BDP, but not azelastine, treatment significantly reduced the percent of eosinophils recovered in nasal lavage (p < 0.05). Neither azelastine nor BDP protected against the increase in bronchial responsiveness to methacholine occurring during the pollen season. CONCLUSION: We demonstrated that both azelastine and BDP are effective treatments for nasal symptoms of seasonal allergic rhinitis after 4 weeks of therapy. However, we were not able to demonstrate an antiinflammatory activity of nasally administered azelastine. Nasal therapy with azelastine and BDP did not block the increase in bronchial responsiveness to methacholine caused by seasonal allergen exposure.
机译:背景:我们比较了鼻氮卓斯汀(0.56 mg /天),鼻倍氯米松双丙酸酯(BDP,200微克/天)和安慰剂对一组季节性症状,鼻细胞学和花粉季节中支气管反应性增加的影响。仅具有花粉过敏性鼻炎病史的受试者。方法:本研究由氮卓斯汀组的9名受试者,BDP组的13名受试者和安慰剂组的13名受试者完成。随机给予治疗6周。每个受试者记录整个花粉季节的每日鼻,眼和胸部症状以及额外的治疗要求。每个受试者在花粉季节的4周后洗鼻。在花粉季节之前和4周之前测量支气管对乙酰甲胆碱的反应性。反应以刺激性剂量表示,该剂量引起以微摩尔计的1秒内强迫呼气量下降20%。结果:与接受安慰剂治疗的受试者相比,接受氮卓斯汀治疗的受试者在第4周的鼻部症状明显减少(p <0.05),而经BDP治疗的受试者在第4周的鼻部症状(p <0.05)和第5周(p <0.05)较少。 。两种治疗方法均大大减少了对其他药物的需求。 BDP而非氮卓斯汀的治疗显着降低了通过鼻灌洗恢复的嗜酸性粒细胞百分比(p <0.05)。氮卓斯汀和BDP都不能防止在花粉季节发生的对乙酰甲胆碱的支气管反应性增加。结论:我们证明,治疗4周后,氮卓斯汀和BDP均可有效治疗季节性变应性鼻炎的鼻部症状。但是,我们无法证明鼻腔给药氮卓斯汀的抗炎活性。氮卓斯汀和BDP的鼻腔治疗不能阻止季节性变应原暴露引起的支气管对乙酰甲胆碱的反应性增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号